Bulletin from Swedish Orphan Biovitrum’s (“Sobi”) Annual General Meeting (AGM)

2017-05-04

The Sobi AGM was convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:


Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,794,687,847.

The board members and the chief executive officer were discharged from liability for the financial year 2016.


Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Schikan were re-elected for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.

The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.

Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.


Principles for remuneration for the management, long-term incentive programme, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM approved the guidelines for remuneration for the management proposed by the Board.

The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive programme, and hedging arrangements in respect of the programme including a directed issue of no more than 496,760 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,497,125 own common shares to programme participants.

The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.

The Board’s proposal regarding transfer of no more than 158,563 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Programme 2014, was also approved by the AGM.

For full details on each proposal adopted by the AGM, please refer to www.sobi.com.

------

 


About Sobi™
 
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact: 
Media relations      Investor relations
Linda Holmström, Senior Communications Manager  Jörgen Winroth, Vice President, Head of Investor Relations
T: + 46 708 73 40 95, + 46 8 697 31 74   T: +1 347 224 0819, +1 212 579 0506, +46 8 697 2135
linda.holmstrom@sobi.com jorgen.winroth@sobi.com 

The information was released for public distribution on May 4, 2017 at 17:45 CET.

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne